PCSA Stock Risk & Deep Value Analysis
Processa Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PCSA Stock
We analyzed Processa Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PCSA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PCSA Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is the failure of NGC-Cap's Phase 2 interim analysis. Given the company's extremely tight financial position and reliance on clinical success, a negative outcome would likely lead to a substantial stock price collapse and potential operational cessation or fire-sale of assets.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Extremely low market capitalization (approx. $7.5M) for a clinical-stage biotech, indicating high speculative risk.
- ⚠
Persistent net losses and significant cash burn, requiring continuous capital raises (implied from 2022 data and Q3 2024 cash runway).
- ⚠
Absence of recent Q1 2026 10-Q in search results, hindering current financial assessment.
- ⚠
Investment thesis entirely dependent on unproven clinical trial outcomes with inherently low probabilities.
Upcoming Risk Events
- 📅
Negative or inconclusive results from NGC-Cap Phase 2 interim analysis
- 📅
Failure to secure adequate financing leading to significant dilution or operational delays
- 📅
Regulatory setbacks for any pipeline candidates
When to Reconsider
- 🚪
NGC-Cap Phase 2 interim analysis reports negative or underwhelming results.
- 🚪
Company announces substantial share dilution (e.g., >50% increase in shares outstanding) without commensurate clinical progress.
- 🚪
Cash on hand reported below 6 months of operating expenses.
Unlock PCSA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Processa Pharmaceuticals Inc (PCSA) Do?
Market Cap
$7.29M
Sector
Healthcare
Industry
Biotechnology
Employees
10
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Visit Processa Pharmaceuticals Inc WebsiteInvestment Thesis
Processa Pharmaceuticals presents an ultra-high-risk, high-reward investment opportunity centered on its oncology pipeline. A positive interim analysis for NGC-Cap in H1 2026 could provide significant validation, potentially re-rating the stock due to its extremely low current valuation. This is a binary bet for investors with a very high-risk tolerance looking for moonshot biotech returns.
Is PCSA Stock Undervalued?
Unlock the full AI analysis for PCSA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PCSA Price Targets & Strategy
12-Month Target
$8.00
Bull Case
$18.00
Bear Case
$1.00
Valuation Basis
Based on speculative valuation of NGC-Cap pipeline post-positive Phase 2 data, assigning a 3x increase to perceived enterprise value ($7.5M to ~$22.5M) on successful interim analysis (not guaranteed).
Entry Strategy
Given extreme volatility, dollar-cost average into any significant dips below current levels. Consider entry between $2.00-$2.50 if the risk appetite allows, acknowledging high speculative nature.
Exit Strategy
Take 50% profit if stock reaches $8.00-$10.00 following positive clinical news. Implement a hard stop-loss at $1.50 if NGC-Cap data disappoints or significant dilution occurs.
Portfolio Allocation
1-2% for aggressive risk tolerance only, as a highly speculative satellite position.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is PCSA Financially Healthy?
Profitability
Gross Margin
32.24%
Operating Margin
-2707.69%
Net Margin
-2981.25%
Return on Equity
-257.81%
Revenue Growth
520000000000.00%
EPS
$-17.05
Balance Sheet
Current Ratio
2.54
Quick Ratio
2.48
Total Debt
$5.20B
Cash & Equivalents
$5.20B
Cash Flow
Operating Cash Flow
$5.20B
Free Cash Flow
$5.20B
EBITDA
$5.20B
Other
Beta (Volatility)
1.00
Does PCSA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Nascent/Potentially Expanding (dependent on successful clinical development and patent protection)
Moat Sources
1 Identified
The durability of any potential moat is highly uncertain, entirely dependent on successful clinical trial outcomes, regulatory approvals, and the strength and breadth of their future intellectual property. Currently, no durable moat exists.
Moat Erosion Risks
- •Clinical trial failure or inconclusive results for lead candidates
- •Patent challenges or expiration from larger pharmaceutical companies
- •Launch of superior competing therapies by rivals
PCSA Competitive Moat Analysis
Sign up to see competitive advantages
PCSA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, likely low retail investor interest due to micro-cap status and high-risk profile.
Institutional Sentiment
Neutral, no analyst ratings or institutional ownership data found, suggesting minimal institutional coverage.
Insider Activity (Form 4)
CEO George K. Ng bought 1,843 shares at $2.97/share on April 15, 2026. CFO Russell Skibsted bought 2,190 shares at $2.69/share recently. This indicates sustained insider confidence.
Options Flow
Normal options activity (no specific unusual activity identified in search results).
Earnings Intelligence
Next Earnings
Estimated late May / early June 2026 (for Q1 2026, based on historical filing patterns)
Surprise Probability
Low (no analyst estimates or historical patterns provided to gauge surprise)
Historical Earnings Pattern
Insufficient data to establish a consistent historical earnings reaction pattern. Volatility expected around any significant news.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (No specific direct competitors or market share data identified for PCSA's specific pipeline drugs at this early stage in search results. The oncology drug development market is highly fragmented with many large and small players.)
Market Share Trend
N/A (Pre-commercial, currently has no market share).
Valuation vs Peers
Difficult to compare without current financial metrics, but likely trades at a significant discount to established biotech firms due to pre-revenue status and high clinical risk, while potentially at a premium to other distressed micro-caps due to pipeline promise.
Competitive Advantages
- •Potential novel mechanisms for enhancing existing chemotherapy (if successful)
- •Proprietary intellectual property for pipeline candidates (unproven)
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive PCSA Stock Higher?
Near-Term (0-6 months)
- •NGC-Cap Phase 2 interim analysis results (expected H1 2026, by June 30, 2026)
- •Q1 2026 10-Q filing (pending as of May 7, 2026)
Medium-Term (6-18 months)
- •Advancement of NGC-Cap to Phase 3 studies (if Phase 2 successful)
- •Progress on other pipeline candidates (PCSA-01, PCSA-02)
Long-Term (18+ months)
- •Regulatory approval and commercialization of lead drug candidate (NGC-Cap)
- •Potential strategic partnerships for drug development or distribution
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for PCSA?
- ✓
Official announcement and detailed results of NGC-Cap Phase 2 interim analysis
- ✓
Terms and size of any new financing rounds (to assess dilution impact)
- ✓
Any indications of new strategic partnerships or licensing agreements
Bull Case Analysis
Sign up free to see the bull case
Competing with PCSA
See how Processa Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Processa Pharmaceuticals Inc PCSA | $7.3M | 4.0 | — | $5.2B | -2981.3% | 520000000000.0% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Processa Pharmaceuticals Inc Makes Money
Processa Pharmaceuticals is a clinical-stage biotechnology company focused on developing a portfolio of next-generation chemotherapy drugs designed to improve the effectiveness and reduce the toxicity of current cancer treatments. The company's business model is entirely centered on the research, development, and eventual commercialization of these drug candidates. Should their drugs successfully navigate the stringent clinical trial and regulatory approval processes, revenue would be generated through direct sales of approved therapies or through licensing agreements with larger pharmaceutical companies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Processa Pharmaceuticals Inc (PCSA)?
As of May 7, 2026, Processa Pharmaceuticals Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Processa Pharmaceuticals Inc?
Processa Pharmaceuticals Inc's market capitalization is approximately $7.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Processa Pharmaceuticals Inc use?
PCSA is the ticker symbol for Processa Pharmaceuticals Inc. The company trades on the NCM.
What is the risk level for PCSA stock?
Our analysis rates Processa Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Processa Pharmaceuticals Inc's revenue growing?
Processa Pharmaceuticals Inc has reported revenue growth of 520000000000.0%. The company is showing strong top-line momentum.
Is PCSA stock profitable?
Processa Pharmaceuticals Inc has a profit margin of -2981.3%. The company is currently unprofitable.
How often is the PCSA DVR analysis updated?
Our AI-powered analysis of Processa Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 7, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PCSA (Processa Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.